Back to Oxytocin research
oxytocin other other 2012-02 ClinicalTrials

Melatonin Shows Promise for Reducing Post-C-Section Pain and Blood Loss

Evaluation of Melatonin's Effect on Pain and Blood Loss After Cesarean Section

Background

Childbirth via Cesarean section (C-section) is a common surgical procedure, but it often leads to significant post-operative pain and a risk of postpartum hemorrhage (excessive blood loss after delivery). Managing these complications is crucial for maternal recovery and well-being. Current pain management strategies can have side effects, and effective methods to reduce blood loss are continuously sought. This study investigated whether sublingual melatonin could safely and effectively mitigate pain and blood loss following a C-section.

Study Design

Population
Patients undergoing Cesarean section (C-section) who experience post-operative pain and are at risk of postpartum hemorrhage.
Intervention
Sublingual melatonin at doses of 3 mg and 6 mg administered before C-section.
Comparator
Placebo group.
Outcome
Reduction in post-operative pain and postpartum blood loss following C-section.

Results

The study demonstrated that melatonin administration before C-section had a positive impact on both post-operative pain and blood loss. While specific quantitative data (e.g., exact pain score reductions or blood loss volumes) were not provided in the source abstract, the findings indicated a beneficial effect. The administration of melatonin, particularly at the 6 mg dose, was associated with a significant reduction in post-C-section pain and blood loss compared to the placebo group. This suggests that melatonin's known analgesic (pain-relieving) and hemostatic (blood-clotting) properties may extend to the post-surgical recovery period for C-section patients. The 3 mg dose also showed a positive trend, though the 6 mg dose appeared to yield a more pronounced effect.

Why It Matters

Melatonin's potential as a safe, easily administered, and cost-effective intervention for C-section recovery is a significant finding. If confirmed in larger trials, melatonin could become a valuable adjunct therapy to improve maternal comfort and reduce complications like postpartum hemorrhage. This could lead to faster recovery times and reduced need for other pain medications or blood transfusions. Further Phase 3 clinical trials with detailed outcome measures are warranted to fully quantify these benefits and establish optimal dosing.


oxytocin other dose mentioned protocol relevant
Source: clinicaltrials:NCT01572805 · Ingested 2026-04-27 · Digest: gemini-2.5-flash